|
|
||||||||
Papers In Press, published online ahead of print October 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 29, 2002
BPMS/NIA, National Institutes of Health, Bethesda, MD 20892
Corresponding Author: plsetn{at}mail.nih.gov
We examined brain phospholipid metabolism in mice in which the cytosolic phospholipase A2 (cPLA2, Type IV, 85 kDa) was knocked out (cPLA2(-/-) mice). Compared with controls, these mice demonstrated altered brain concentrations of several phospholipids, reduced esterified linoleate, arachidonate and docosahexaenoate in choline glycerophospholipid, and reduced esterified arachidonate in phosphatidylinositol. Unanesthetized cPLA2(-/-) mice had reduced rates of incorporation of unlabeled arachidonate from plasma and from the brain arachidonoyl-CoA pool into ethanolamine glycerophospholipid and choline glycerophospholipid, but elevated rates into phosphatidylinositol. These differences corresponded to altered turnover and metabolic loss of esterified brain arachidonate. These results suggests that cPLA2 is necessary to maintain normal brain concentrations of phospholipids and of their esterified polyunsaturated fatty acids. Reduced esterified arachidonate and docosahexaenoate may account for the resistance of the cPLA2(-/-) mouse to middle cerebral artery occlusion, and should influence membrane fluidity, neuroinflammation, signal transduction and other brain processes.
Revised on September 3, 2002
Accepted on September 17, 2002
Brain lipid metabolism in the cytosolic phospholipase A2 knockout mouse
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. J. Mancuso, H. F. Sims, X. Han, C. M. Jenkins, S. P. Guan, K. Yang, S. H. Moon, T. Pietka, N. A. Abumrad, P. H. Schlesinger, et al. Genetic Ablation of Calcium-independent Phospholipase A2{gamma} Leads to Alterations in Mitochondrial Lipid Metabolism and Function Resulting in a Deficient Mitochondrial Bioenergetic Phenotype J. Biol. Chem., November 30, 2007; 282(48): 34611 - 34622. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ma, R. Langenbach, S. I. Rapoport, and M. Basselin Altered brain lipid composition in cyclooxygenase-2 knockout mouse J. Lipid Res., April 1, 2007; 48(4): 848 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Farooqui, W.-Y. Ong, and L. A. Horrocks Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders Pharmacol. Rev., September 1, 2006; 58(3): 591 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Y. Golovko and E. J. Murphy Uptake and metabolism of plasma-derived erucic acid by rat brain J. Lipid Res., June 1, 2006; 47(6): 1289 - 1297. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Ellis, E. J. Murphy, D. C. Mitchell, M. Y. Golovko, F. Scaglia, G. C. Barcelo-Coblijn, and R. L. Nussbaum Mitochondrial Lipid Abnormality and Electron Transport Chain Impairment in Mice Lacking {alpha}-Synuclein Mol. Cell. Biol., November 15, 2005; 25(22): 10190 - 10201. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sapirstein, H. Saito, S. J. Texel, T. A. Samad, E. O'Leary, and J. V. Bonventre Cytosolic phospholipase A2{alpha} regulates induction of brain cyclooxygenase-2 in a mouse model of inflammation Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1774 - R1782. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Bazan Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor J. Lipid Res., December 1, 2003; 44(12): 2221 - 2233. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |